In radiological tests, breast abnormalities are categorized from BIRADS-1 to BIRADS-5 based on the likelihood of cancer. Abnormalities identified as BIRADS-3 require follow-up every 3 to 6 months, while those diagnosed as BIRADS-4a and higher require a biopsy.
The limitations of Sonography in detecting these abnormalities often result in delays in patient treatment and necessary biopsies. The Impedimetric Tumor Detection System (ITDS) device is a new and innovative technology where a specially designed probe is inserted into the patient’s body under ultrasound guidance and removed after a few seconds, with the test results instantly displayed. ITDS can be particularly beneficial for young patients with dense breast tissue, especially those with BI-RADS3 masses that are difficult to evaluate with mammography. Additionally, patients with BI-RADS3 masses and a family history of breast cancer can also benefit from this system. This device also has important applications in distinguishing simple fibroadenomas from complex fibroadenomas and phyllodes tumors.
Advantages and Superiority of the Impedimetric Tumor Detection System
ITDS has displayed encouraging results in a study involving 138 breast masses, achieving a sensitivity rate of 95%. This indicates that the device correctly identified the presence of tumors in 95 out of 100 cases. Additionally, the system has a specificity of 89% and an overall accuracy of 90%. These metrics indicate that ITDS has the potential to enhance the precision and efficacy of breast cancer screening, resulting in timelier detection and improved outcomes for patients.
Hospital Tech (ITDS)
Hospitech Cancer Care Innovations Company is at the forefront of revolutionizing cancer diagnosis with its state-of-the-art devices. These devices, including the Cancer Diagnostic Probe (CDP), (ITDS), Electrical Endoscopy Mass Detection (EMD), and ElectroChemoTherapy (ECT) & Gamma Probe , are designed to enhance the detection and treatment of cancer. Backed by research, publications, and patents, these instruments offer precise results for early diagnosis and improved patient outcomes. The company is dedicated to making a significant impact in the healthcare industry’s battle against cancer, supported by a committed team and unwavering determination.
Impedimetric Tumor Detection System is a revolutionary device that significantly enhances the accuracy of tumor detection. With a sensitivity of 95% and specificity of 89%, it ensures reliable identification of breast tumors, minimizing false negatives and positives. ITDS’s innovative technology has earned several US patents and is recognized in numerous scientific publications. By facilitating early detection, ITDS improves patient outcomes and supports healthcare providers in delivering superior care, making it a valuable investment for any medical facility.
